| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta-Lactamases | 10 | 2018 | 52 | 2.510 |
Why?
|
| Plasmids | 9 | 2019 | 287 | 1.990 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2021 | 143 | 1.340 |
Why?
|
| Bacterial Proteins | 9 | 2018 | 864 | 1.270 |
Why?
|
| Enterobacteriaceae | 6 | 2016 | 21 | 1.190 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 6 | 2018 | 74 | 1.030 |
Why?
|
| DNA Ligases | 8 | 2006 | 13 | 1.020 |
Why?
|
| Cross Infection | 7 | 2018 | 141 | 1.010 |
Why?
|
| Enterobacteriaceae Infections | 5 | 2017 | 23 | 0.970 |
Why?
|
| Colistin | 2 | 2021 | 7 | 0.970 |
Why?
|
| Bacteriological Techniques | 5 | 2016 | 39 | 0.960 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 3 | 2018 | 7 | 0.950 |
Why?
|
| Genome, Bacterial | 4 | 2017 | 139 | 0.940 |
Why?
|
| Saliva | 2 | 2021 | 122 | 0.920 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 7 | 2019 | 44 | 0.840 |
Why?
|
| beta-Lactam Resistance | 4 | 2015 | 11 | 0.830 |
Why?
|
| Sanitary Engineering | 2 | 2018 | 3 | 0.820 |
Why?
|
| Reading | 1 | 2021 | 30 | 0.810 |
Why?
|
| Gene Transfer, Horizontal | 3 | 2019 | 35 | 0.780 |
Why?
|
| Multilocus Sequence Typing | 2 | 2016 | 11 | 0.730 |
Why?
|
| Umbilical Cord | 1 | 2018 | 40 | 0.670 |
Why?
|
| Klebsiella pneumoniae | 5 | 2019 | 34 | 0.650 |
Why?
|
| Microbiological Techniques | 2 | 2019 | 24 | 0.650 |
Why?
|
| Water Microbiology | 1 | 2018 | 13 | 0.640 |
Why?
|
| Molecular Epidemiology | 3 | 2016 | 53 | 0.640 |
Why?
|
| Pandemics | 2 | 2022 | 740 | 0.630 |
Why?
|
| Blood Transfusion | 1 | 2018 | 157 | 0.620 |
Why?
|
| Bacterial Infections | 4 | 2017 | 182 | 0.620 |
Why?
|
| Fetus | 1 | 2018 | 226 | 0.610 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.600 |
Why?
|
| Anti-Bacterial Agents | 10 | 2021 | 746 | 0.580 |
Why?
|
| Infant, Premature | 1 | 2018 | 290 | 0.570 |
Why?
|
| Mass Screening | 1 | 2021 | 617 | 0.560 |
Why?
|
| Staphylococcus aureus | 4 | 2017 | 263 | 0.560 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.540 |
Why?
|
| Hemolysin Proteins | 2 | 2012 | 34 | 0.530 |
Why?
|
| DNA Helicases | 7 | 2006 | 79 | 0.530 |
Why?
|
| Infection Control | 1 | 2016 | 115 | 0.530 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.520 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 68 | 0.520 |
Why?
|
| Achievement | 1 | 2014 | 29 | 0.510 |
Why?
|
| Bacteria | 3 | 2018 | 447 | 0.510 |
Why?
|
| Down Syndrome | 1 | 2014 | 53 | 0.510 |
Why?
|
| Bacterial Toxins | 2 | 2012 | 111 | 0.510 |
Why?
|
| Specimen Handling | 3 | 2021 | 98 | 0.500 |
Why?
|
| Motor Skills | 1 | 2014 | 71 | 0.490 |
Why?
|
| Humans | 52 | 2022 | 86601 | 0.490 |
Why?
|
| Yeasts | 1 | 2013 | 49 | 0.470 |
Why?
|
| DNA-Binding Proteins | 8 | 2006 | 1208 | 0.460 |
Why?
|
| Self Care | 1 | 2014 | 164 | 0.460 |
Why?
|
| Mycoses | 1 | 2013 | 46 | 0.460 |
Why?
|
| Klebsiella Infections | 3 | 2019 | 25 | 0.460 |
Why?
|
| Child Development | 1 | 2014 | 163 | 0.450 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2012 | 5 | 0.440 |
Why?
|
| DNA Repair | 8 | 2006 | 356 | 0.410 |
Why?
|
| Th17 Cells | 1 | 2012 | 80 | 0.410 |
Why?
|
| Hemochromatosis | 1 | 2011 | 11 | 0.410 |
Why?
|
| Yersinia pestis | 1 | 2011 | 24 | 0.400 |
Why?
|
| Plague | 1 | 2011 | 27 | 0.400 |
Why?
|
| Host-Pathogen Interactions | 2 | 2014 | 231 | 0.390 |
Why?
|
| Escherichia coli | 4 | 2017 | 597 | 0.380 |
Why?
|
| Acinetobacter Infections | 2 | 2016 | 17 | 0.370 |
Why?
|
| Hospitals | 3 | 2018 | 294 | 0.370 |
Why?
|
| Acinetobacter baumannii | 2 | 2016 | 26 | 0.370 |
Why?
|
| Histoplasmosis | 1 | 2009 | 25 | 0.350 |
Why?
|
| Opportunistic Infections | 1 | 2009 | 59 | 0.340 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2008 | 13 | 0.340 |
Why?
|
| Gram-Negative Bacteria | 2 | 2020 | 35 | 0.340 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2019 | 49 | 0.330 |
Why?
|
| Hematoma | 1 | 2009 | 104 | 0.330 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2019 | 194 | 0.320 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 166 | 0.310 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2018 | 23 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 5 | 2017 | 853 | 0.300 |
Why?
|
| Genetic Therapy | 1 | 2009 | 342 | 0.300 |
Why?
|
| Fatal Outcome | 4 | 2019 | 293 | 0.300 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2017 | 13 | 0.300 |
Why?
|
| Health Personnel | 2 | 2021 | 202 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 683 | 0.290 |
Why?
|
| Cell Nucleolus | 1 | 2006 | 23 | 0.290 |
Why?
|
| Carrier State | 2 | 2017 | 39 | 0.290 |
Why?
|
| DNA Ligase ATP | 8 | 2006 | 9 | 0.270 |
Why?
|
| Adenosine Triphosphatases | 1 | 2006 | 153 | 0.270 |
Why?
|
| Disease Outbreaks | 3 | 2016 | 154 | 0.270 |
Why?
|
| Antigens, Nuclear | 6 | 2001 | 25 | 0.270 |
Why?
|
| Ubiquitin | 1 | 2006 | 93 | 0.260 |
Why?
|
| DNA Damage | 3 | 2006 | 366 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2001 | 381 | 0.250 |
Why?
|
| Bacterial Typing Techniques | 2 | 2014 | 28 | 0.250 |
Why?
|
| Nasopharynx | 2 | 2021 | 47 | 0.240 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 977 | 0.240 |
Why?
|
| Whole Genome Sequencing | 3 | 2019 | 76 | 0.240 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2022 | 69 | 0.240 |
Why?
|
| Oxidative Stress | 1 | 2006 | 447 | 0.230 |
Why?
|
| Intestines | 2 | 2017 | 411 | 0.210 |
Why?
|
| Genes, Bacterial | 3 | 2017 | 198 | 0.210 |
Why?
|
| Epidemiological Monitoring | 3 | 2017 | 39 | 0.210 |
Why?
|
| Polymyxin B | 1 | 2021 | 4 | 0.210 |
Why?
|
| Exome | 1 | 2022 | 127 | 0.200 |
Why?
|
| Medical Informatics Applications | 1 | 2021 | 9 | 0.200 |
Why?
|
| Mouth | 1 | 2021 | 48 | 0.200 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 21 | 0.190 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 17 | 0.190 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 41 | 0.190 |
Why?
|
| Metagenomics | 2 | 2018 | 83 | 0.190 |
Why?
|
| Fetal Death | 1 | 2000 | 56 | 0.190 |
Why?
|
| Recombination, Genetic | 3 | 2000 | 439 | 0.190 |
Why?
|
| Infant, Newborn | 4 | 2018 | 2378 | 0.190 |
Why?
|
| Cholangiocarcinoma | 1 | 2020 | 66 | 0.180 |
Why?
|
| Hepatocytes | 1 | 2020 | 127 | 0.180 |
Why?
|
| Hospices | 1 | 2019 | 7 | 0.180 |
Why?
|
| Time Factors | 6 | 2017 | 5209 | 0.180 |
Why?
|
| Cell Line | 5 | 2006 | 2468 | 0.180 |
Why?
|
| Azabicyclo Compounds | 1 | 2019 | 3 | 0.180 |
Why?
|
| Ceftazidime | 1 | 2019 | 7 | 0.180 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2018 | 64 | 0.180 |
Why?
|
| Hospice Care | 1 | 2019 | 39 | 0.180 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 1990 | 0.180 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 52 | 0.180 |
Why?
|
| Sphingomonas | 1 | 2018 | 4 | 0.170 |
Why?
|
| Drug Contamination | 1 | 2019 | 12 | 0.170 |
Why?
|
| Virus Inactivation | 1 | 2018 | 4 | 0.170 |
Why?
|
| Adenoviridae Infections | 1 | 2019 | 15 | 0.170 |
Why?
|
| Fetoscopy | 1 | 2018 | 8 | 0.170 |
Why?
|
| Constriction | 1 | 2018 | 27 | 0.170 |
Why?
|
| Disease Reservoirs | 1 | 2018 | 22 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 879 | 0.170 |
Why?
|
| Blood Cells | 1 | 2018 | 33 | 0.170 |
Why?
|
| Granuloma | 1 | 2019 | 65 | 0.170 |
Why?
|
| Disinfection | 1 | 2018 | 14 | 0.170 |
Why?
|
| Acute Pain | 1 | 2018 | 10 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2021 | 122 | 0.160 |
Why?
|
| Pain Management | 1 | 2019 | 127 | 0.160 |
Why?
|
| Coinfection | 1 | 2018 | 58 | 0.160 |
Why?
|
| Quality Control | 1 | 2018 | 117 | 0.160 |
Why?
|
| Female | 11 | 2022 | 44507 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2022 | 535 | 0.160 |
Why?
|
| Viruses | 1 | 2018 | 78 | 0.160 |
Why?
|
| Infant, Premature, Diseases | 1 | 2018 | 78 | 0.160 |
Why?
|
| Mice | 16 | 2020 | 11352 | 0.160 |
Why?
|
| Chaplaincy Service, Hospital | 1 | 2017 | 4 | 0.160 |
Why?
|
| Enterobacter cloacae | 1 | 2017 | 8 | 0.150 |
Why?
|
| Caregivers | 2 | 2019 | 151 | 0.150 |
Why?
|
| Adenoviridae | 1 | 2019 | 345 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2021 | 319 | 0.150 |
Why?
|
| Clergy | 1 | 2017 | 24 | 0.150 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 71 | 0.150 |
Why?
|
| Auranofin | 1 | 2016 | 1 | 0.150 |
Why?
|
| Child, Hospitalized | 1 | 2017 | 33 | 0.150 |
Why?
|
| Hypothermia | 1 | 2016 | 26 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2019 | 238 | 0.150 |
Why?
|
| Pain Measurement | 1 | 2018 | 321 | 0.150 |
Why?
|
| Prevalence | 2 | 2018 | 1239 | 0.150 |
Why?
|
| Telemedicine | 1 | 2019 | 169 | 0.150 |
Why?
|
| Germany | 1 | 2016 | 72 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 199 | 0.140 |
Why?
|
| Body Temperature | 1 | 2016 | 124 | 0.140 |
Why?
|
| Neurons | 5 | 2001 | 1546 | 0.140 |
Why?
|
| Spirituality | 1 | 2017 | 87 | 0.140 |
Why?
|
| Nocardia | 1 | 2016 | 2 | 0.140 |
Why?
|
| Aeromonas hydrophila | 1 | 2016 | 1 | 0.140 |
Why?
|
| Enterococcus faecium | 1 | 2016 | 32 | 0.140 |
Why?
|
| Nocardia Infections | 1 | 2016 | 5 | 0.140 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 54 | 0.140 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 35 | 0.140 |
Why?
|
| Nuclear Proteins | 7 | 2004 | 696 | 0.140 |
Why?
|
| Chronic Pain | 1 | 2018 | 145 | 0.140 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 10 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2016 | 103 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 73 | 0.130 |
Why?
|
| Shigella | 1 | 2015 | 1 | 0.130 |
Why?
|
| Yersinia | 1 | 2015 | 2 | 0.130 |
Why?
|
| Dysentery, Bacillary | 1 | 2015 | 2 | 0.130 |
Why?
|
| Male | 12 | 2022 | 40956 | 0.130 |
Why?
|
| Yersinia Infections | 1 | 2015 | 5 | 0.130 |
Why?
|
| Salmonella | 1 | 2015 | 14 | 0.130 |
Why?
|
| Virulence Factors | 2 | 2014 | 108 | 0.130 |
Why?
|
| Anal Canal | 1 | 2016 | 89 | 0.130 |
Why?
|
| Salmonella Infections | 1 | 2015 | 18 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 185 | 0.130 |
Why?
|
| Liver | 2 | 2011 | 1229 | 0.130 |
Why?
|
| Perioperative Care | 1 | 2016 | 161 | 0.130 |
Why?
|
| Classification | 1 | 2015 | 54 | 0.130 |
Why?
|
| Staphylococcal Protein A | 1 | 2014 | 38 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2014 | 33 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2014 | 34 | 0.120 |
Why?
|
| Parents | 1 | 2017 | 272 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 735 | 0.120 |
Why?
|
| Genomics | 2 | 2022 | 720 | 0.120 |
Why?
|
| Neoplasms | 3 | 2019 | 2897 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 191 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 4 | 2013 | 3092 | 0.120 |
Why?
|
| Critical Care | 1 | 2016 | 370 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2018 | 751 | 0.110 |
Why?
|
| Skin | 1 | 2016 | 554 | 0.110 |
Why?
|
| Animals | 17 | 2020 | 26581 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2018 | 8475 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 160 | 0.110 |
Why?
|
| Fibroblasts | 6 | 2001 | 729 | 0.110 |
Why?
|
| Microbiota | 2 | 2016 | 381 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 255 | 0.100 |
Why?
|
| Infant | 2 | 2017 | 3045 | 0.100 |
Why?
|
| ADAM Proteins | 1 | 2011 | 11 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2232 | 0.100 |
Why?
|
| Translocation, Genetic | 3 | 2001 | 265 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2017 | 3611 | 0.100 |
Why?
|
| Ferritins | 1 | 2011 | 29 | 0.100 |
Why?
|
| Mice, Knockout | 8 | 2011 | 1924 | 0.100 |
Why?
|
| Autopsy | 1 | 2011 | 116 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 93 | 0.100 |
Why?
|
| DNA, Bacterial | 3 | 2017 | 236 | 0.100 |
Why?
|
| DNA-Activated Protein Kinase | 4 | 2004 | 16 | 0.100 |
Why?
|
| Research Personnel | 1 | 2011 | 67 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1673 | 0.100 |
Why?
|
| Iron | 1 | 2011 | 164 | 0.100 |
Why?
|
| Adult | 7 | 2019 | 25640 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 418 | 0.090 |
Why?
|
| Middle Aged | 7 | 2019 | 25017 | 0.090 |
Why?
|
| Pneumonia | 1 | 2011 | 179 | 0.090 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2011 | 204 | 0.090 |
Why?
|
| Dependovirus | 1 | 2009 | 33 | 0.090 |
Why?
|
| Histoplasma | 1 | 2009 | 13 | 0.090 |
Why?
|
| Retroperitoneal Space | 1 | 2009 | 38 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1621 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 2 | 2000 | 103 | 0.090 |
Why?
|
| United States | 5 | 2021 | 6665 | 0.090 |
Why?
|
| Blood | 1 | 2008 | 69 | 0.080 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 2 | 1999 | 20 | 0.080 |
Why?
|
| Culture Media | 2 | 2020 | 147 | 0.080 |
Why?
|
| Central Nervous System | 2 | 2000 | 151 | 0.080 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 2 | 1999 | 37 | 0.080 |
Why?
|
| Muscles | 1 | 2008 | 194 | 0.080 |
Why?
|
| Cause of Death | 1 | 2009 | 277 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 183 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2009 | 439 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2019 | 224 | 0.080 |
Why?
|
| Phenotype | 4 | 2022 | 2377 | 0.080 |
Why?
|
| Lymphocytes | 2 | 2000 | 464 | 0.080 |
Why?
|
| Radiography | 1 | 2009 | 813 | 0.070 |
Why?
|
| Child | 2 | 2017 | 6926 | 0.070 |
Why?
|
| RecQ Helicases | 1 | 2006 | 6 | 0.070 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2014 | 131 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 46 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1384 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2207 | 0.070 |
Why?
|
| Lung | 1 | 2012 | 1170 | 0.070 |
Why?
|
| Adolescent | 2 | 2017 | 8979 | 0.070 |
Why?
|
| Ku Autoantigen | 6 | 2001 | 12 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 305 | 0.070 |
Why?
|
| Cell Cycle | 4 | 2000 | 502 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 3030 | 0.070 |
Why?
|
| HeLa Cells | 1 | 2006 | 498 | 0.070 |
Why?
|
| Carbapenems | 2 | 2015 | 9 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2014 | 1004 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1196 | 0.060 |
Why?
|
| Enzyme Stability | 1 | 2004 | 39 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2006 | 579 | 0.060 |
Why?
|
| Gene Rearrangement | 3 | 2000 | 170 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 279 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 416 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2001 | 104 | 0.060 |
Why?
|
| DNA Primers | 1 | 2004 | 543 | 0.060 |
Why?
|
| Genotype | 2 | 2016 | 1850 | 0.060 |
Why?
|
| Apoptosis | 5 | 2001 | 1683 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2001 | 329 | 0.050 |
Why?
|
| Cellular Senescence | 2 | 2000 | 94 | 0.050 |
Why?
|
| Genes, Lethal | 2 | 2000 | 53 | 0.050 |
Why?
|
| Mutagenesis | 2 | 2001 | 199 | 0.050 |
Why?
|
| Chromosome Aberrations | 2 | 2001 | 387 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 456 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2004 | 1106 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2021 | 73 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2001 | 131 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 7 | 0.050 |
Why?
|
| Ataxia Telangiectasia | 1 | 2001 | 11 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2001 | 252 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 16 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2001 | 229 | 0.050 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 6 | 0.050 |
Why?
|
| Polyethylene Terephthalates | 1 | 2020 | 17 | 0.050 |
Why?
|
| Oropharynx | 1 | 2020 | 15 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 4210 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 145 | 0.050 |
Why?
|
| Quinine | 1 | 2000 | 6 | 0.050 |
Why?
|
| Babesiosis | 1 | 2000 | 4 | 0.050 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2000 | 18 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2062 | 0.050 |
Why?
|
| Clindamycin | 1 | 2000 | 13 | 0.050 |
Why?
|
| Base Sequence | 1 | 2004 | 2330 | 0.050 |
Why?
|
| Antimalarials | 1 | 2000 | 20 | 0.050 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1999 | 29 | 0.050 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1999 | 24 | 0.050 |
Why?
|
| Genome | 2 | 2000 | 372 | 0.050 |
Why?
|
| Sarcoma | 1 | 2001 | 211 | 0.050 |
Why?
|
| Directed Molecular Evolution | 1 | 2019 | 20 | 0.040 |
Why?
|
| Virus Replication | 1 | 2021 | 319 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2000 | 168 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 97 | 0.040 |
Why?
|
| Hospitals, Federal | 1 | 2018 | 1 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 1999 | 115 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 2501 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 71 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2019 | 130 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 95 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 1998 | 64 | 0.040 |
Why?
|
| Neonatal Nursing | 1 | 2018 | 2 | 0.040 |
Why?
|
| Respiratory System | 1 | 2019 | 116 | 0.040 |
Why?
|
| Water Supply | 1 | 2018 | 60 | 0.040 |
Why?
|
| Cell Division | 1 | 2000 | 696 | 0.040 |
Why?
|
| Nursing Assessment | 1 | 2018 | 20 | 0.040 |
Why?
|
| Gene Targeting | 1 | 1998 | 72 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 71 | 0.040 |
Why?
|
| Internet | 1 | 2021 | 312 | 0.040 |
Why?
|
| Microscopy | 1 | 2019 | 87 | 0.040 |
Why?
|
| Necrosis | 1 | 2019 | 204 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 751 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 122 | 0.040 |
Why?
|
| Nanopores | 1 | 2017 | 6 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 136 | 0.040 |
Why?
|
| Genes, MDR | 1 | 2017 | 7 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 826 | 0.040 |
Why?
|
| Nucleosides | 1 | 2017 | 22 | 0.040 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2017 | 27 | 0.040 |
Why?
|
| B-Lymphocytes | 3 | 2014 | 724 | 0.040 |
Why?
|
| Workflow | 1 | 2017 | 77 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 93 | 0.040 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2016 | 20 | 0.040 |
Why?
|
| Software | 1 | 2021 | 654 | 0.040 |
Why?
|
| Heart | 1 | 1999 | 539 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2000 | 673 | 0.040 |
Why?
|
| Biological Transport | 1 | 2017 | 396 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 5416 | 0.040 |
Why?
|
| Acinetobacter | 1 | 2016 | 4 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2016 | 303 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1999 | 710 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2016 | 51 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2019 | 502 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1161 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2014 | 15 | 0.030 |
Why?
|
| Calcium | 1 | 1999 | 1156 | 0.030 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2014 | 27 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1753 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 455 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2014 | 109 | 0.030 |
Why?
|
| Germinal Center | 1 | 2014 | 55 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 428 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2014 | 80 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 319 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2014 | 332 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 373 | 0.030 |
Why?
|
| Germ-Free Life | 1 | 2013 | 69 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 126 | 0.030 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2013 | 40 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2013 | 85 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 94 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 273 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 219 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2013 | 103 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 372 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 391 | 0.030 |
Why?
|
| Symbiosis | 1 | 2013 | 118 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 679 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 615 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 878 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2013 | 209 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 504 | 0.030 |
Why?
|
| ADAM10 Protein | 1 | 2011 | 7 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2011 | 26 | 0.030 |
Why?
|
| Mutation | 2 | 2019 | 3967 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 480 | 0.020 |
Why?
|
| Cadherins | 1 | 2011 | 151 | 0.020 |
Why?
|
| Epithelium | 1 | 2011 | 319 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2001 | 2818 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 539 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2001 | 1458 | 0.020 |
Why?
|
| T-Lymphocytes | 3 | 2001 | 1195 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1351 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2600 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2013 | 629 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1376 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 920 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 1920 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 5974 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2001 | 7 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2357 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 85 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2001 | 52 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 365 | 0.010 |
Why?
|
| Diencephalon | 1 | 2000 | 6 | 0.010 |
Why?
|
| Babesia | 1 | 2000 | 2 | 0.010 |
Why?
|
| Hematocrit | 1 | 2000 | 68 | 0.010 |
Why?
|
| Antibodies, Protozoan | 1 | 2000 | 34 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 121 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2000 | 86 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2000 | 136 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2000 | 207 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 229 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 427 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 279 | 0.010 |
Why?
|
| Genes, Essential | 1 | 1998 | 19 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1998 | 72 | 0.010 |
Why?
|
| Growth | 1 | 1999 | 43 | 0.010 |
Why?
|
| Creatinine | 1 | 2000 | 338 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2000 | 249 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 244 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1998 | 121 | 0.010 |
Why?
|
| Nervous System | 1 | 1999 | 86 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2001 | 388 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2000 | 894 | 0.010 |
Why?
|
| Thymus Neoplasms | 1 | 1997 | 41 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 18402 | 0.010 |
Why?
|
| Homeostasis | 1 | 1999 | 409 | 0.010 |
Why?
|
| Fetal Growth Retardation | 1 | 1997 | 66 | 0.010 |
Why?
|
| Body Patterning | 1 | 1998 | 209 | 0.010 |
Why?
|
| Myocardium | 1 | 1999 | 529 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 1685 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2000 | 584 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1999 | 592 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 1531 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 1999 | 536 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 777 | 0.010 |
Why?
|